A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913 Article

Chinnaiyan, Prakash, Won, Minhee, Wen, Patrick Y et al. (2018). A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913 . NEURO-ONCOLOGY, 20(5), 666-673. 10.1093/neuonc/nox209

Open Access International Collaboration

cited authors

  • Chinnaiyan, Prakash; Won, Minhee; Wen, Patrick Y; Rojiani, Amyn M; Werner-Wasik, Maria; Shih, Helen A; Ashby, Lynn S; Yu, Hsiang-Hsuan Michael; Stieber, Volker W; Malone, Shawn C; Fiveash, John B; Mohile, Nimish A; Ahluwalia, Manmeet S; Wendland, Merideth M; Stella, Philip J; Kee, Andrew Y; Mehta, Minesh P

sustainable development goals

authors

publication date

  • May 1, 2018

published in

keywords

  • Clinical Neurology
  • INHIBITION
  • Life Sciences & Biomedicine
  • MAMMALIAN TARGET
  • Neurosciences & Neurology
  • Oncology
  • PTEN-DEFICIENT
  • RAD001
  • RADIATION-THERAPY
  • RADIOTHERAPY
  • RAPAMYCIN
  • SIGNALING PATHWAY
  • Science & Technology
  • TEMOZOLOMIDE
  • TRIAL
  • everolimus
  • glioblastoma
  • mTOR inhibition
  • phase II trial
  • radiation sensitizer

Digital Object Identifier (DOI)

publisher

  • OXFORD UNIV PRESS INC

start page

  • 666

end page

  • 673

volume

  • 20

issue

  • 5